Lasofoxifene Effective for Dyspareunia
Dyspareunia is a significant problem in postmenopausal women. A recent study at George Washington University found that up to 92% of sexually active women reported moderate or severe symptoms. Forty percent of women cited dyspareunia as their most bothersome problem associated with vaginal atrophy. A recent Phase III trial showed that lasofoxifene can significantly improve the symptoms of dyspareunia as well as increase bone mineral density (BMD) in postmenopausal women.
EHR-based models show promise in predicting postpartum depression
December 24th 2024Recent research published highlights the potential of electronic health record data to improve postpartum depression diagnosis, offering a step toward better mental health outcomes for birthing parents.
Read More
Midlife sexual health boosts for nonheterosexual women reported
December 23rd 2024A recent study highlights improved sexual function and reduced distress among nonheterosexual women during menopause compared to their heterosexual counterparts, shedding light on how sexual identity impacts well-being.
Read More
